U.S., Jan. 18 -- ClinicalTrials.gov registry received information related to the study (NCT03801278) titled 'An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer' on Jan. 9.
Brief Summary: This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
Study Type: Expanded Access
Condition: Recurrent Bladder Cancer
Intervention: Drug: FPA144
Bemarituzumab administration every two weeks
Other Name: Bemarituzumab
Sponsor: Five Prime Therapeutics, Inc.
Information provided by (Responsible Party): Five Prime Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily D...